Will Merck's Bold Hepatitis C Play Pay Off?

Merck's deal for Idenix is all about establishing long-term viability in the emerging HCV space

Jun 10, 2014 at 2:30PM

There is a significant (and sometimes larger than expected) gap between "looks like it can compete" and actually competing with a rival that has both strong data and a big head start, but Merck (NYSE:MRK) continues to show that it is serious about competing with Gilead (NASDAQ:GILD) and AbbVie (NYSE:ABBV) in the market for advanced therapies for hepatitis C (or HCV). The company's nearly $4 billion acquisition of Idenix (NASDAQ:IDIX) is an expensive affirmation of that long-term focus, but one that could start paying off before the end of the decade.

The deal
Merck took the Street flat-footed Monday morning when it announced that it had reached an agreement with Idenix to acquire the HCV-focused biotech for $24.50 per share in cash, or a total deal value of $3.85 billion (about 2% of Merck's enterprise value).

As Idenix had closed Friday at a price of $7.23 and had an average sell-side price target of $7.67, it may be defensible to say that this was not the consensus expected outcome. On the other hand, the shares had been climbing through the month of May and there were rumors that Johnson & Johnson (NYSE: JNJ) and AbbVie both had interest in Idenix. A nearly 240% premium to the recent price would certainly seem to support the idea that Idenix negotiated from a position of strength.

The rationale is in the long term
Idenix is not a deal that is going to help Merck today. The company's strongest pipeline asset, the nucleotide prodrug IDX21437 (or '437) is a Phase II asset (it has successfully completed a Phase I study) and it is not likely that Merck will get it to market (in the form of a combo therapy) before 2017.

It could be well worth the wait for Merck. A small Phase I study showed efficacy that was lower than Gilead's Sovaldi (a 4.2 to 4.3 log drop versus 4.5), but close enough to be competitive. By no means do these data "prove" that '437 can anchor a combo regimen, but it does at least raise the potential that Merck can combine it with '5172 and '8742 into a fast-acting and highly effective one-pill/once-daily combo.

As a reminder, Merck reported data back in April that indicated that the combination of '5172 (an NS3/4A protease inhibitor) and '8742 (an NS5A) was highly effective in chronic HCV genotype 1 patients. These data were stronger than the Street had been expecting and raised hopes that Merck would be a competitive third entrant in the advanced HCV combo market behind Gilead and AbbVie.

Merck is already under way with the C-SWIFT study that adds Gilead's Sovaldi to that combo, and data from the trial could offer a read-through on the combo potential of '437 (though it is very important to be clear that '437 and Sovaldi are not identical). With '437 in hand, Merck will almost certainly move into clinical studies as a triple therapy, with the goal of an ultra-fast (four to six-week) regimen hitting the market in 2017.

Importantly, Merck will get much better economics on a wholly owned triple therapy. Merck will owe royalties to Novartis for Idenix products that range from the high single-digits to low teens, but that's far better than having to pay the cost of including Solvadi.

Plenty can still go wrong
By no means is it a certainty that Merck now has a great triple combo on the way. There haven't been any safety flags so far with '437, but investors certainly remember how the $2.5 billion deal between Bristol-Myers and Inhibitex blew up in Bristol-Myers' face when safety issues killed the prospects for the lead drug. While the Inhibitex nuc was a guanosine analog ('437 is a uridine analog) and there were preclinical signals of potential problems, the fact remains that safety (or efficacy) issues could still appear along the way; that virology drug trials are more consistent between Phase I, II, and III than oncology drug trials doesn't mean there are no surprises. Along similar lines, Idenix has had its share of clinical failures along the way.

It's also important to note that Gilead has established a very high bar. I never expected Gilead to hold 100% of the HCV market indefinitely (and I don't believe any serious analyst or investor thought so either), but Gilead will have the advantage of significant time-to-market leads and gaining share in the absence of superior data will be challenging. The good news, from Merck's perspective, is that the HCV market is not going away and a second- or third-place position in multibillion dollar global market is well worth the trouble.

The bottom line
Given the premium Merck agreed to pay, and the strategic value of inserting '437 into its existing experimental combo therapy, I don't see a high likelihood of rival bidders. Instead, attention may shift to Achillion Pharmaceuticals as the "last man standing" in the field of potential HCV acquisition targets.

For Merck, this is a deal about the future. Yes, nearly $4 billion is a lot to pay, but even with the strong portfolios at Gilead and AbbVie, there is likely to be enough to go around in the HCV market for this deal to pay for itself over the long term.

Looking for another bold investment? Check out this opportunity
Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out, and some early viewers are claiming its everyday impact could trump the iPod, iPhone, and the iPad. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Apple and Gilead Sciences. The Motley Fool owns shares of Apple and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers